AVANDAMET Drug Patent Profile

When do Avandamet patents expire, and what generic alternatives are available?

Avandamet is a drug marketed by Sb Pharmco and is included in one NDA.

The generic ingredient in AVANDAMET is metformin hydrochloride; rosiglitazone maleate. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; rosiglitazone maleate profile page.

Summary for AVANDAMET

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	14
Patent Applications:	955
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AVANDAMET
What excipients (inactive ingredients) are in AVANDAMET?	AVANDAMET excipients list
DailyMed Link:	AVANDAMET at DailyMed

Recent Clinical Trials for AVANDAMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
Susan G. Komen Breast Cancer Foundation	Phase 1
M.D. Anderson Cancer Center	Phase 1

See all AVANDAMET clinical trials

Paragraph IV (Patent) Challenges for AVANDAMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVANDAMET	Tablets	metformin hydrochloride; rosiglitazone maleate	1 mg/ 500 mg, 2 mg/ 500mg 4 mg/ 500 mg 2 mg/ 1000 mg 4 mg/ 1000 mg	021410	1	2004-10-22

US Patents and Regulatory Information for AVANDAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-004	Aug 25, 2003		DISCN	Yes	No
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002		DISCN	Yes	No
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-005	Aug 25, 2003		DISCN	Yes	No
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-001	Oct 10, 2002		DISCN	Yes	No

Expired US Patents for AVANDAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-004	Aug 25, 2003	8,236,345
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-001	Oct 10, 2002	8,236,345
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-005	Aug 25, 2003	8,236,345
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002	8,236,345

International Patents for AVANDAMET

When does loss-of-exclusivity occur for AVANDAMET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AVANDAMET around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	186724
Australia	2173888
Australia	611938
Brazil	1100841

Supplementary Protection Certificates for AVANDAMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0861666	91298	Luxembourg		91298, EXPIRES: 20210620
0861666	300258	Netherlands		300258, 20160620, EXPIRES: 20210619
0861666	SPC 038/2006	Ireland		SPC 038/2006: 20070528, EXPIRES: 20210619
0861666	07C0006	France		PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728

Last updated: July 24, 2026

AVANDAMET market dynamics and financial trajectory (patent, exclusivity, generic risk, and brand P&L outlook)

AVANDAMET (rosiglitazone maleate + metformin hydrochloride) has exited the active growth phase and now trades as a low-growth, share-sustaining product tied to residual demand and formulary inertia in type 2 diabetes. The financial trajectory is dominated by (1) loss of exclusivity for the component(s) that underpin the combination, (2) the shift to safer, lower-risk diabetes pipelines and branded GLP-1 and SGLT2 agents, and (3) generic cannibalization across strengths and dosage forms. The resulting commercial profile is typically characterized by steady net sales erosion, constrained price realization, and shrinking payer support, with distribution largely reduced to legacy accounts.

Because AVANDAMET is a fixed-dose combination, its market dynamics track the combination brand’s ability to remain on formularies after generic entry of rosiglitazone-containing and metformin-containing products, plus the competitiveness of non-TZDs in US and ex-US markets.

---

Why did AVANDAMET sales decline and what market forces drove share loss?

AVANDAMET’s commercial decline is explained by three reinforcing market forces: class-level risk perception for rosiglitazone (TZD), intensifying therapeutic competition in type 2 diabetes, and generic substitution economics.

What role did rosiglitazone safety risk play in demand erosion?

Rosiglitazone faced longstanding scrutiny around cardiovascular risk. That pressure affected prescriber behavior, payer positioning, and long-term demand. For a combination product, that translates into lower physician adoption and weaker formulary support even when a patient already uses metformin.

How did competitor classes reshape prescribing toward GLP-1 and SGLT2?

Type 2 diabetes treatment has shifted toward incretin-based therapies (GLP-1 receptor agonists, dual GIP/GLP-1 agonists) and SGLT2 inhibitors with demonstrated cardiovascular and renal outcome benefits. These classes moved earlier lines of therapy away from TZDs in many formularies and clinical pathways, limiting incremental uptake for combination metformin/TZD products.

How did generics structurally cap AVANDAMET pricing?

Once generic rosiglitazone and metformin regimens are available, AVANDAMET’s value proposition narrows to convenience. Convenience generally does not overcome payer preference for least-cost alternatives, especially where prescribers can substitute separately priced generics.

---

What is AVANDAMET’s financial trajectory since launch through today?

AVANDAMET’s financial trajectory follows a classic late-life fixed-dose combination pattern:

• High initial adoption driven by mechanism and unmet need in earlier diabetes management.
• Mid-life plateau constrained by safety concerns and increasing clinical competition.
• Late-life decline driven by generic cannibalization and continued migration to GLP-1/SGLT2.

The combination’s unit economics typically deteriorate due to:

• Net price compression as payer discounts and formulary tiers shift to generics.
• Volume loss as patients and new starts move to lower-cost regimens or newer therapeutic classes.
• Reduced promotional spend and tighter distribution, consistent with brands nearing or past patent end.

---

When does AVANDAMET lose exclusivity and what does that mean for revenue?

AVANDAMET exclusivity and patent protection are not robust enough to support a sustained branded revenue stream once generic entry is enabled for rosiglitazone and metformin-containing products.

What patents protect AVANDAMET as a combination product?

AVANDAMET’s enforceability historically depends on a layered patent set that can include:

• Composition claims tied to the fixed-dose combination.
• Formulation and manufacturing claims for specific ratios and dosage strengths.
• Method-of-use claims (less common for combination products, more likely to be generic-friendly once the underlying actives are established).

In late-life, the effective commercial “exclusivity” is usually de facto, not de jure. Even where some incremental formulation patents remain, payer and prescriber switching often accelerates once any generic versions achieve substitution equivalence.

How does generic substitution change revenue curves?

Generic entry typically drives:

• A step-down in net sales after launch.
• Ongoing decline as switches and new prescriptions move to least-cost options.
• Limited brand retention for patients already stable on the fixed combination, usually shrinking as pharmacy benefit managers update formularies and substitution protocols normalize.

---

What generic entry risks exist for AVANDAMET (Paragraph IV, ANDA, and authorized generics)?

Generic entry risk for AVANDAMET is structurally high because it is a fixed-dose combination of established, widely generic actives. The key risk drivers are:

• Availability of generic rosiglitazone and metformin products.
• ANDA feasibility to combine actives at approved strengths.
• Exclusivity carve-outs that may affect specific strengths or dosage forms but rarely prevent broad category-level substitution.

How likely is Paragraph IV litigation to affect AVANDAMET launches?

For long-established combination products, litigation often becomes less central than simple economic substitution. When patents remain, Paragraph IV challenges can delay entry for specific SKUs, but the brand’s overall revenue exposure remains high because market substitution spreads across multiple strengths.

What manufacturing/IP barriers can still block generic supply?

Even if composition and formulation patents exist, they often face generic design-around strategies. For fixed-dose combinations, barriers are most relevant when manufacturing process claims are narrow and tied to specific release, particle attributes, or stability constraints. Once those are weak or expired, generic timelines compress.

---

What is the Orange Book status of AVANDAMET and how does it map to launch timing?

Orange Book status determines which patents are listed for the approved NDA and which could be asserted in ANDA challenges. In practice for late-life fixed-dose combinations:

• Many listed patents are expired or no longer meaningfully enforceable against generic products.
• Remaining patents may be limited in scope to particular dosage forms/strengths or manufacturing details.

The market outcome is a function of whether the generics can navigate around any still-live patents for the relevant SKU(s). If they can, branded revenues decline quickly even without full exclusivity expiration across all listings.

---

How do method-of-use and formulation patents affect AVANDAMET generic design-around?

For combinations of established actives, method-of-use patents are often less durable in blocking generics than composition/formulation claims. Formulation patents can be more operational but still tend to weaken as generic developers replicate the dose and confirm stability/bioequivalence.

Which formulation claims are most likely to be enforceable?

• Specific excipient systems tied to dissolution or stability.
• Release characteristics if the combination is in a modified-release format (AVANDAMET is generally not treated as a novel release platform versus metformin ER).
• Manufacturing process parameters that are hard to replicate, though this is uncommon for broad fixed-dose combos.

How do generics typically design around formulation barriers?

• Use equivalent excipients permitted in approvals.
• Adjust manufacturing parameters within acceptable ranges.
• Rely on bioequivalence and stability data rather than copying proprietary process steps.

---

Which companies are active in AVANDAMET competition and what is the likely payer strategy?

AVANDAMET competes against:

• Generics of rosiglitazone + metformin components and separate dosing alternatives.
• Newer branded and generic diabetes classes that gain preferred tiers.

Payers typically pursue:

• Lowest net cost under pharmacy benefit management.
• Step therapy and prior authorization favoring outcome-based or guideline-aligned therapies.
• Restricted access for TZDs where safety or newer therapy advantages are recognized.

This shifts share away from AVANDAMET even where it remains “covered,” because coverage does not equal preferred placement.

---

How does AVANDAMET compare with other type 2 diabetes fixed-dose combinations?

Fixed-dose diabetes combinations generally behave similarly:

• Early growth as a convenience product.
• Mid-life resilience while brand differentiation remains.
• Late-life decline after generic entry and guideline migration.

AVANDAMET’s class headwinds from rosiglitazone magnify decline versus fixed-dose combinations that rely on better-perceived or guideline-favored classes.

---

What litigation and settlement dynamics have shaped the AVANDAMET market?

For products with long life cycles, the most commercially relevant litigation outcome is usually the timing and scope of generic entry. Settlement dynamics can:

• Narrow entry to certain strengths.
• Grant “carve-outs” in which specific SKUs launch later.
• Convert exclusivity disputes into delayed or phased launches.

Even if litigation creates short delays, the broader trend still reflects generic economics and payer migration to newer therapies.

---

What does AVANDAMET’s FDA status imply for current availability and competitiveness?

Once multiple ANDA approvals exist and substitution is enabled across strengths, FDA approval status becomes less about future exclusivity and more about:

• Ongoing supply stability.
• Label language consistency.
• Bioequivalence standards that make interchangeability routine.

The competitive impact shifts toward pharmacy and payer switching behavior rather than clinical adoption.

---

Revenue exposure: where is AVANDAMET most at risk financially?

Revenue exposure concentrates in:

• The US market, because the generics substitution and payer controls are strongest.
• Strengths where generic equivalents exist first, producing the fastest decline in net price and volume.

Operationally, brand P&L exposure correlates with:

• How quickly formularies move AVANDAMET off preferred tiers.
• Whether pharmacy chains substitute automatically at point of sale.
• Whether prescribers continue fixed-dose reliance versus prescribing separate generics.

---

Key Takeaways

• AVANDAMET’s market dynamics are dominated by generic substitution economics of rosiglitazone and metformin and by therapeutic migration toward GLP-1 and SGLT2 classes.
• Financial trajectory is consistent with a late-life fixed-dose combination: net sales erosion, price compression, and shrinking payer support.
• Exclusivity and patent estates are unlikely to prevent broad category substitution in the long run; any remaining enforceability typically affects only specific SKUs or delays, not the overall demand curve.
• The competitive front is less about “brand vs brand” and more about “any cost-effective generic regimen vs newer guideline-favored therapies.”

---

FAQs

1) Is AVANDAMET still commonly prescribed for type 2 diabetes?

Its usage is generally constrained to legacy patients and specific formulary pockets as clinicians and payers favor GLP-1/SGLT2 and other guideline-aligned strategies.

2) Does AVANDAMET face stronger generic pressure than single-ingredient metformin ER products?

Yes, because fixed-dose combinations have straightforward least-cost alternatives using separate generics at similar convenience.

3) Can AVANDAMET maintain market share through formulary coverage alone?

Coverage alone does not stop substitution. Share retention depends on preferred tier placement and net price competitiveness against generics.

4) What patient segments are most likely to remain on a rosiglitazone-containing regimen?

Patients stable on existing regimens in older treatment lines, where clinicians are less likely to change therapy solely for convenience, though this declines as formularies tighten.

5) What is the main driver of AVANDAMET’s remaining commercial value?

Residual convenience and switching frictions, outweighed over time by net cost pressure and treatment guideline shifts.

---

References

No sources were provided in the prompt, and no external patent/Orange Book/financial data for AVANDAMET could be cited within the constraints.